Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nesiritide and VO2 Max in Heart Failure
NCT00240084Phase 2Completed
- Sponsor
- University of Rochester
- Start
- Jul 2003
- Primary completion
- Nov 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nesiritide in heart failure (HF), sponsored by University of Rochester. Primary endpoint: Peak VO2 at 24 hours. Started Jul 2003; status: completed.
02
Drugs
nesiritide
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT00240084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00240084.